| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 35, 813-816, Copyright © 1989 by American Association for Clinical Chemistry
J Joven, E Vilella, B Costa, PR Turner, C Richart and L Masana
Hospital de Sant Joan de Reus y Joan XXIII de Tarragona, Facultad de Medicina de Reus, Universidad de Barcelona, Spain.
The triglyceride and cholesterol content of total, very-low-, intermediate-, low-, and high-density lipoproteins, and of apolipoproteins (apo) Al, All, B, Cll, Clll, and E were determined in plasma from 107 patients with clinically well-controlled diabetes and from 66 age- and weight-matched healthy normal subjects. The diabetic patients were separated into two groups: those with insulin-dependent diabetes mellitus (IDDM, type 1, n = 24) and those with non-insulin- dependent diabetes mellitus (NIDDM, type 2, n = 83). The latter group contained two subgroups: those treated by diet (type 2d, n = 42) or by insulin (type 2i, n = 41). High-density lipoprotein cholesterol was increased in IDDM patients, and decreased in NIDDM patients relative to control subjects. Mean apo Al values in IDDM patients were higher than in their respective controls and in NIDDM patients. Concentrations of apo B, Clll, and E were higher in all diabetic patients than in the healthy controls, but those of apo Cll did not differ statistically between diabetics and nondiabetics. Although total plasma cholesterol and triglyceride concentrations were apparently near normal values in patients with good glycemic control, we found a persistent increase of intermediate-density lipoproteins (remnants) in all the diabetic groups studied. This factor may be related to the perceived increased cardiovascular risk in these individuals.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  L. Juntti-Berggren, E. Refai, I. Appelskog, M. Andersson, G. Imreh, N. Dekki, S. Uhles, L. Yu, W. J. Griffiths, S. Zaitsev, et al. Apolipoprotein CIII promotes Ca2+-dependent {beta} cell death in type 1 diabetes PNAS, July 6, 2004; 101(27): 10090 - 10094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Maggi, N. Minicuci, T. Harris, L. Motta, M. Baldereschi, A. Di Carlo, D. Inzitari, and G. Crepaldi High Plasma Insulin and Lipids Profile in Older Individuals: The Italian Longitudinal Study on Aging J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2001; 56(4): 236M - 242. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Joven, X. Cliville, J. Camps, E. Espinel, J. Simo, E. Vilella, and A. Oliver Plasma protein abnormalities in nephrotic syndrome: effect on plasma colloid osmotic pressure and viscosity Clin. Chem., July 1, 1997; 43(7): 1223 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T.K. Singh, D. L. Rainwater, S. M. Haffner, J. L. VandeBerg, W. R. Shelledy, P. H. Moore Jr, and T. D. Dyer Effect of Diabetes on Lipoprotein Size Arterioscler Thromb Vasc Biol, November 1, 1995; 15(11): 1805 - 1811. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Joven and E. Vilella Serum Levels of Lipoprotein(a) in Patients With Well-Controlled Non-Insulin-Dependent Diabetes Mellitus JAMA, March 6, 1991; 265(9): 1113 - 1114. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
